A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Rheumatoid Arthritis
Interventions
DRUG

MRC375

MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.

DRUG

Matching Placebo

Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.

DRUG

MRC375 150mg

MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks

Trial Locations (19)

23185

The Center for Excellence in Aging and Geriatric Health, Williamsburg

28144

PMG Research of Salisbury, Salisbury

32132

Riverside Clinical Research, Edgewater

33156

Global Clinical Professionals, Miami

34491

Lakeview Medical Research, Summerfield

34684

The Arthritis Center, Palm Harbor

36608

Mobile Diagnostic Center Rheumatology, Mobile

42303

Trial Concierge, Owensboro

44130

Paramount Medical Research & Consulting, LLC, Middleburg Heights

45439

Providence Health Partners, Dayton

66219

Analan Clinical Research, Lenexa

68114

Quality Clinical Research, Inc., Omaha

89123

Advanced BioMedical Research of America, Las Vegas

89502

Arthritis Center of Reno, Reno

90036

Axis Clinical Trials, Los Angeles

90720

Trial Concierge/Pacific Clinical Studies, Los Alamitos

90806

Valerius Medical Group, Long Beach

98502

South Puget Sound Clinical Research Center, Olympia

99336

Apex Clinical Research, Kennewick

All Listed Sponsors
collaborator

Camargo Pharmaceutical Services

INDUSTRY

collaborator

Clin Data Services

UNKNOWN

collaborator

Harrison Clinical Research

INDUSTRY

collaborator

BARC Global Central Laboratory

UNKNOWN

collaborator

Bilcare Global Clinical Supplies

UNKNOWN

lead

Molecular Research Center, Inc.

INDUSTRY